A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients

Therapeutic Drug Monitoring

Volumn 31, Issue 2, 2009, Pages 239-246

  Ghassabian, Sussan ^a   Chetty, Manoranjenni ^a   Tattam, Bruce N ^a   Chem, Mraci C ^b   Glen, John ^b   Rahme, Jeannie ^b   Stankovic, Zvijezdana ^a   Ramzan, Iqbal ^a   Murray, Michael ^a   McLachlan, Andrew J ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Macquarie Hospital   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Cytochrome P450 activity; LC MS MS; Mass spectrometry; Phenotyping cocktail

Indexed keywords

1 HYDROXYMIDAZOLAM; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 5 HYDROXYOMEPRAZOLE; CAFFEINE; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DEXTRORPHAN; DRUG METABOLITE; LOSARTAN; MIDAZOLAM; OMEPRAZOLE; PARAXANTHINE; UNCLASSIFIED DRUG; CYTOCHROME P450;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; PERFORMANCE; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; TANDEM MASS SPECTROMETRY; BIOTRANSFORMATION; GENETICS;

BIOTRANSFORMATION; CAFFEINE; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; HUMANS; LOSARTAN; MIDAZOLAM; OMEPRAZOLE; PHENOTYPE; TANDEM MASS SPECTROMETRY;

EID: 65349122355     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318197e1bf     Document Type: Article

References (20)

1. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002;360:1155-1162.
2. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10:187-216.
3. Tucker GT, Rostami-Hodjegan A, Jackson PR. Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. Xenobiotica. 1998;28:1255-1273.
4. Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos. 2005;33:1859-1866.
5. Ma JD, Nafziger AN, Villano SA, et al. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006;50:1130-1135.
6. Johnson BM, Song IH, Adkison KK, et al. Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified Cooperstown 5 + 1 cocktail. J Clin Pharmacol. 2006;46:577-587.
7. Ryu JY, Song IS, Sunwoo YE, et al. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther. 2007;82:531-540.
8. Zgheib NK, Frye RF, Tracy TS, et al. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin Pharmacol Ther. 2006;80:257-263.
9. Yin OQ, Lam SS, Lo CM, et al. Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies. Rapid Commun Mass Spectrom. 2004;18:2921-2933.
10. Chainuvati S, Nafziger AN, Leeder JS, et al. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the "Cooperstown 5 + 1 cocktail."' Clin Pharmacol Ther. 2003;74:437-447.
11. Christensen M, Andersson K, Dalen P, et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther. 2003;73:517-528.
12. Scott RJ, Palmer J, Lewis IA, et al. Determination of a "GW cocktail" of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom. 1999;13:2305-2319.
13. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther. 2007;81:270-283.
14. Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol. 1999;57:465-480.
15. Berthou F, Goasduff T, Lucas D, et al. Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics. 1995;5:72-79.
16. Wong M, Balleine RL, Collins M, et al. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther. 2004;75:529-538.
17. Streetman DS, Bleakley JF, Kim JS, et al. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail." Clin Pharmacol Ther. 2000;68:375-383.
18. Kim JS, Nafziger AN, Tsunoda SM, et al. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol. 2002;42:376-382.
19. Lin YS, Lockwood GF, Graham MA, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics. 2001;11:781-791.
20. Lee TC, Charles B, Steer P, et al. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther. 1997;61:628-640.